Pacific Biosciences of California, Inc. Share Price
Stocks
PACB
US69404D1081
Advanced Medical Equipment & Technology
|
Market Closed -
Nasdaq
21:00:00 05/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 2.430 USD | -4.71% |
|
-16.21% | +29.95% |
| Market Cap | 793M 706M 646M 588M 1.11B 74.9B 1.14B 7.76B 3.1B 39.67B 2.98B 2.91B 125B | P/E 2026 * |
-5.73x | P/E 2027 * | -5.54x |
|---|---|---|---|---|---|
| Enterprise Value | 1.26B 1.12B 1.03B 936M 1.77B 119B 1.81B 12.35B 4.94B 63.14B 4.74B 4.63B 199B | EV / Sales 2026 * |
7.95x | EV / Sales 2027 * | 7.16x |
| Free-Float |
91.14% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| PACB | Delayed | |
CBOE
| PACB | Real-time | |
|
Tradegate
| P09 | Real-time | |
|
Xetra
| P09 | Delayed | |
|
Börse Stuttgart
| P09 | Delayed | |
|
Boerse Muenchen
| P09 | Real-time | |
|
Deutsche Boerse AG
| P09 | Delayed | |
|
Mexican S.E.
| PACB * | End-of-day quote |
Last Transcript: Pacific Biosciences of California, Inc.
| 1 day | -4.71% | ||
| 1 week | -16.21% | ||
| Current month | -6.72% | ||
| 1 month | -15.33% | ||
| 3 months | +86.92% | ||
| 6 months | +53.80% | ||
| Current year | +29.95% |
| 1 week | 2.23 |  | 2.82 |
| 1 month | 1.7 | | 3.44 |
| Current year | 1.07 | | 3.44 |
| 1 year | 1.07 | | 3.44 |
| 3 years | 0.85 | | 10.65 |
| 5 years | 0.85 | | 29.94 |
| 10 years | 0.85 | | 53.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark van Oene
CEO | Chief Executive Officer | 53 | 04/08/2026 |
Jonas Korlach
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2012 |
Todd Friedman
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Bill Ericson
BRD | Director/Board Member | 67 | 31/12/2003 |
Randy Livingston
BRD | Director/Board Member | 72 | 31/12/2008 |
Marshall Mohr
BRD | Director/Board Member | 69 | 17/01/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/10/26 | Exercice | Chief Financial Officer | 1,661,815 | 0.5346% | ||
| 17/08/26 | Sell | Chief Executive Officer | -26,911 | 0.0087% | ||
| 10/08/26 | Free | Chief Executive Officer | 2,457,018 | 0.7911% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.71% | -16.21% | +26.89% | -64.26% | 793M | |
| -4.14% | -4.55% | +19.26% | +48.77% | 262B | |
| -3.66% | -4.49% | +6.66% | +15.76% | 165B | |
| -2.82% | +4.40% | -14.59% | +68.98% | 167B | |
| -2.58% | +4.57% | -54.86% | -15.47% | 66.41B | |
| +1.46% | +6.76% | +21.70% | +50.25% | 57.28B | |
| +0.33% | +5.66% | -8.63% | -6.21% | 56.02B | |
| -3.04% | -5.17% | +17.04% | +59.75% | 49.95B | |
| -0.17% | -0.08% | +5.03% | +58.09% | 50.29B | |
| -3.11% | -5.62% | +21.81% | +79.69% | 45.94B | |
| Average | -2.02% | +0.97% | +4.03% | +29.54% | 92.07B | |
| Weighted average by Cap. | -2.50% | +2.33% | +3.20% | +41.18% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 159M 141M 129M 118M 222M 15B 228M 1.55B 621M 7.94B 596M 583M 25.06B | 184M 164M 150M 137M 258M 17.4B 265M 1.8B 721M 9.21B 691M 676M 29.08B |
| Net income | -138M -123M -113M -102M -193M -13.05B -198M -1.35B -540M -6.91B -518M -507M -21.8B | -147M -131M -120M -109M -206M -13.9B -211M -1.44B -576M -7.36B -552M -540M -23.22B |
| Net Debt | 469M 418M 382M 348M 656M 44.31B 674M 4.59B 1.84B 23.47B 1.76B 1.72B 74.05B | 527M 469M 429M 391M 737M 49.76B 757M 5.16B 2.06B 26.35B 1.98B 1.93B 83.16B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/11/26 | US$2.430 | -4.71% | 20,045,198 |
| 04/11/26 | US$2.550 | +4.51% | 20,974,348 |
| 03/11/26 | US$2.440 | +4.05% | 6,256,511 |
| 02/11/26 | US$2.345 | -9.98% | 9,099,749 |
| 30/10/26 | US$2.605 | -10.17% | 13,737,066 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PACB Stock
Select your edition
All financial news and data tailored to specific country editions
